Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Combining Cell-Free Protein Synthesis and NMR Into a Tool to Study Capsid Assembly Modulation.

Wang S, Fogeron ML, Schledorn M, Dujardin M, Penzel S, Burdette D, Berke JM, Nassal M, Lecoq L, Meier BH, Böckmann A.

Front Mol Biosci. 2019 Aug 8;6:67. doi: 10.3389/fmolb.2019.00067. eCollection 2019.

2.

Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects.

Vandenbossche J, Jessner W, van den Boer M, Biewenga J, Berke JM, Talloen W, De Zwart L, Snoeys J, Yogaratnam J.

Adv Ther. 2019 Sep;36(9):2450-2462. doi: 10.1007/s12325-019-01017-1. Epub 2019 Jul 2.

PMID:
31267367
3.

Novel Potent Capsid Assembly Modulators Regulate Multiple Steps of the Hepatitis B Virus Life Cycle.

Lahlali T, Berke JM, Vergauwen K, Foca A, Vandyck K, Pauwels F, Zoulim F, Durantel D.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00835-18. doi: 10.1128/AAC.00835-18. Print 2018 Oct.

4.

Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV).

Vandyck K, Rombouts G, Stoops B, Tahri A, Vos A, Verschueren W, Wu Y, Yang J, Hou F, Huang B, Vergauwen K, Dehertogh P, Berke JM, Raboisson P.

J Med Chem. 2018 Jul 26;61(14):6247-6260. doi: 10.1021/acs.jmedchem.8b00654. Epub 2018 Jul 3.

PMID:
29906396
5.

Characterization of a dengue NS4B inhibitor originating from an HCV small molecule library.

Hernandez-Morales I, Geluykens P, Clynhens M, Strijbos R, Goethals O, Megens S, Verheyen N, Last S, McGowan D, Coesemans E, De Boeck B, Stoops B, Devogelaere B, Pauwels F, Vandyck K, Berke JM, Raboisson P, Simmen K, Lory P, Van Loock M.

Antiviral Res. 2017 Nov;147:149-158. doi: 10.1016/j.antiviral.2017.10.011. Epub 2017 Oct 14.

PMID:
29037976
6.

Antiviral profiling of the capsid assembly modulator BAY41-4109 on full-length HBV genotype A-H clinical isolates and core site-directed mutants in vitro.

Berke JM, Tan Y, Verbinnen T, Dehertogh P, Vergauwen K, Vos A, Lenz O, Pauwels F.

Antiviral Res. 2017 Aug;144:205-215. doi: 10.1016/j.antiviral.2017.06.016. Epub 2017 Jun 21.

PMID:
28647474
7.

Capsid Assembly Modulators Have a Dual Mechanism of Action in Primary Human Hepatocytes Infected with Hepatitis B Virus.

Berke JM, Dehertogh P, Vergauwen K, Van Damme E, Mostmans W, Vandyck K, Pauwels F.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00560-17. doi: 10.1128/AAC.00560-17. Print 2017 Aug.

8.

Discovery of 1-((2R,4aR,6R,7R,7aR)-2-Isopropoxy-2-oxidodihydro-4H,6H-spiro[furo[3,2-d][1,3,2]dioxaphosphinine-7,2'-oxetan]-6-yl)pyrimidine-2,4(1H,3H)-dione (JNJ-54257099), a 3'-5'-Cyclic Phosphate Ester Prodrug of 2'-Deoxy-2'-Spirooxetane Uridine Triphosphate Useful for HCV Inhibition.

Jonckers TH, Tahri A, Vijgen L, Berke JM, Lachau-Durand S, Stoops B, Snoeys J, Leclercq L, Tambuyzer L, Lin TI, Simmen K, Raboisson P.

J Med Chem. 2016 Jun 23;59(12):5790-8. doi: 10.1021/acs.jmedchem.6b00382. Epub 2016 Jun 3.

PMID:
27181575
9.

Nucleotide prodrugs of 2'-deoxy-2'-spirooxetane ribonucleosides as novel inhibitors of the HCV NS5B polymerase.

Jonckers TH, Vandyck K, Vandekerckhove L, Hu L, Tahri A, Van Hoof S, Lin TI, Vijgen L, Berke JM, Lachau-Durand S, Stoops B, Leclercq L, Fanning G, Samuelsson B, Nilsson M, Rosenquist Å, Simmen K, Raboisson P.

J Med Chem. 2014 Mar 13;57(5):1836-44. doi: 10.1021/jm4015422. Epub 2014 Jan 6.

PMID:
24345201
10.

Discovery and early development of TMC647055, a non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase.

Cummings MD, Lin TI, Hu L, Tahri A, McGowan D, Amssoms K, Last S, Devogelaere B, Rouan MC, Vijgen L, Berke JM, Dehertogh P, Fransen E, Cleiren E, van der Helm L, Fanning G, Nyanguile O, Simmen K, Van Remoortere P, Raboisson P, Vendeville S.

J Med Chem. 2014 Mar 13;57(5):1880-92. doi: 10.1021/jm401396p. Epub 2013 Nov 8.

PMID:
24144360
11.

A cellular replicon-based phenotyping assay to determine susceptibility of hepatitis C virus clinical isolates to NS3/4A protease inhibitors.

Vijgen L, Verbeeck J, Van Kerckhove B, Berke JM, Koletzki D, Fanning G, Lenz O.

Methods Mol Biol. 2013;1030:105-17. doi: 10.1007/978-1-62703-484-5_9.

PMID:
23821263
12.

Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202).

Lenz O, Vijgen L, Berke JM, Cummings MD, Fevery B, Peeters M, De Smedt G, Moreno C, Picchio G.

J Hepatol. 2013 Mar;58(3):445-51. doi: 10.1016/j.jhep.2012.10.028. Epub 2012 Nov 7.

PMID:
23142061
13.

TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage.

Devogelaere B, Berke JM, Vijgen L, Dehertogh P, Fransen E, Cleiren E, van der Helm L, Nyanguile O, Tahri A, Amssoms K, Lenz O, Cummings MD, Clayton RF, Vendeville S, Raboisson P, Simmen KA, Fanning GC, Lin TI.

Antimicrob Agents Chemother. 2012 Sep;56(9):4676-84. doi: 10.1128/AAC.00245-12. Epub 2012 Jun 18.

14.

Finger loop inhibitors of the HCV NS5b polymerase. Part II. Optimization of tetracyclic indole-based macrocycle leading to the discovery of TMC647055.

Vendeville S, Lin TI, Hu L, Tahri A, McGowan D, Cummings MD, Amssoms K, Canard M, Last S, Van den Steen I, Devogelaere B, Rouan MC, Vijgen L, Berke JM, Dehertogh P, Fransen E, Cleiren E, van der Helm L, Fanning G, Van Emelen K, Nyanguile O, Simmen K, Raboisson P.

Bioorg Med Chem Lett. 2012 Jul 1;22(13):4437-43. doi: 10.1016/j.bmcl.2012.04.113. Epub 2012 Apr 30.

PMID:
22633687
15.

Finger-loop inhibitors of the HCV NS5b polymerase. Part 1: Discovery and optimization of novel 1,6- and 2,6-macrocyclic indole series.

McGowan D, Vendeville S, Lin TI, Tahri A, Hu L, Cummings MD, Amssoms K, Berke JM, Canard M, Cleiren E, Dehertogh P, Last S, Fransen E, Van Der Helm E, Van den Steen I, Vijgen L, Rouan MC, Fanning G, Nyanguile O, Van Emelen K, Simmen K, Raboisson P.

Bioorg Med Chem Lett. 2012 Jul 1;22(13):4431-6. doi: 10.1016/j.bmcl.2012.03.097. Epub 2012 Apr 3.

PMID:
22542193
16.

Structure-based macrocyclization yields hepatitis C virus NS5B inhibitors with improved binding affinities and pharmacokinetic properties.

Cummings MD, Lin TI, Hu L, Tahri A, McGowan D, Amssoms K, Last S, Devogelaere B, Rouan MC, Vijgen L, Berke JM, Dehertogh P, Fransen E, Cleiren E, van der Helm L, Fanning G, Van Emelen K, Nyanguile O, Simmen K, Raboisson P, Vendeville S.

Angew Chem Int Ed Engl. 2012 May 7;51(19):4637-40. doi: 10.1002/anie.201200110. Epub 2012 Mar 30. No abstract available.

PMID:
22473861
17.

MAPPIT as a high-throughput screening assay for modulators of protein-protein interactions in HIV and HCV.

Van Schoubroeck B, Van Acker K, Dams G, Jochmans D, Clayton R, Berke JM, Lievens S, Van der Heyden J, Tavernier J.

Methods Mol Biol. 2012;812:295-307. doi: 10.1007/978-1-61779-455-1_18.

PMID:
22218868
18.

Antiviral activity and mode of action of TMC647078, a novel nucleoside inhibitor of the hepatitis C virus NS5B polymerase.

Berke JM, Vijgen L, Lachau-Durand S, Powdrill MH, Rawe S, Sjuvarsson E, Eriksson S, Götte M, Fransen E, Dehertogh P, Van den Eynde C, Leclercq L, Jonckers TH, Raboisson P, Nilsson M, Samuelsson B, Rosenquist Å, Fanning GC, Lin TI.

Antimicrob Agents Chemother. 2011 Aug;55(8):3812-20. doi: 10.1128/AAC.00214-11. Epub 2011 May 16.

19.

2'-Deoxy-2'-spirocyclopropylcytidine revisited: a new and selective inhibitor of the hepatitis C virus NS5B polymerase.

Jonckers TH, Lin TI, Buyck C, Lachau-Durand S, Vandyck K, Van Hoof S, Vandekerckhove LA, Hu L, Berke JM, Vijgen L, Dillen LL, Cummings MD, de Kock H, Nilsson M, Sund C, Rydegård C, Samuelsson B, Rosenquist A, Fanning G, Van Emelen K, Simmen K, Raboisson P.

J Med Chem. 2010 Nov 25;53(22):8150-60. doi: 10.1021/jm101050a. Epub 2010 Oct 29.

PMID:
21033671
20.

In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.

Lenz O, Verbinnen T, Lin TI, Vijgen L, Cummings MD, Lindberg J, Berke JM, Dehertogh P, Fransen E, Scholliers A, Vermeiren K, Ivens T, Raboisson P, Edlund M, Storm S, Vrang L, de Kock H, Fanning GC, Simmen KA.

Antimicrob Agents Chemother. 2010 May;54(5):1878-87. doi: 10.1128/AAC.01452-09. Epub 2010 Feb 22.

21.

Development of a high-content screening assay to identify compounds interfering with the formation of the hepatitis C virus replication complex.

Berke JM, Fenistein D, Pauwels F, Bobbaers R, Lenz O, Lin TI, Krausz E, Fanning G.

J Virol Methods. 2010 May;165(2):268-76. doi: 10.1016/j.jviromet.2010.02.007. Epub 2010 Feb 11.

PMID:
20153373
22.

1a/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus.

Nyanguile O, Devogelaere B, Vijgen L, Van den Broeck W, Pauwels F, Cummings MD, De Bondt HL, Vos AM, Berke JM, Lenz O, Vandercruyssen G, Vermeiren K, Mostmans W, Dehertogh P, Delouvroy F, Vendeville S, VanDyck K, Dockx K, Cleiren E, Raboisson P, Simmen KA, Fanning GC.

J Virol. 2010 Mar;84(6):2923-34. doi: 10.1128/JVI.01980-09. Epub 2010 Jan 13.

23.

Suppression of short interfering RNA-mediated gene silencing by the structural proteins of hepatitis C virus.

Ji J, Glaser A, Wernli M, Berke JM, Moradpour D, Erb P.

J Gen Virol. 2008 Nov;89(Pt 11):2761-6. doi: 10.1099/vir.0.2008/002923-0.

PMID:
18931073
24.

Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex.

Brass V, Berke JM, Montserret R, Blum HE, Penin F, Moradpour D.

Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14545-50. doi: 10.1073/pnas.0807298105. Epub 2008 Sep 17.

25.

Hepatitis C virus comes full circle: production of recombinant infectious virus in tissue culture.

Berke JM, Moradpour D.

Hepatology. 2005 Dec;42(6):1264-9. Review. No abstract available.

PMID:
16317703
26.
27.

Supplemental Content

Loading ...
Support Center